A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older
Author:
Brandon J. Essink,Wim Vermeulen,Coralie Andrade,Richard de Rooij,Leah Isakov,Daniela Casula,Frank R. Albano
© 2025 The Authors. Published by Elsevier Ltd.